SYNTAX II: Initial outcomes of FFR/iFR and IVUS guided PCI with last generation DES in 3 vessel patients

Original Title: iFR/FFR and IVUS-guided percutaneous coronary revascularization with new-generation DES in patients with de novo three-vessel disease: 30-day outcomes of the SYNTAX II trial. Presenter: P. W. Serruys.   The European Society of Cardiology guidelines recommend PCI for patients with multivessel disease and a Syntax score. A prospective, multicenter, single arm study was carried<a href="https://solaci.org/en/2016/05/23/syntax-ii-initial-outcomes-of-ffr-ifr-and-ivus-guided-pci-with-last-generation-des-in-3-vessel-patients/" title="Read more" >...</a>

VELETI II: PCI to Intermediate coronary SVG lesions with DES

Original Title: Sealing intermediate non-obstructive coronary SVG lesions with DES as a new approach to maintaining vein graft patency and reducing cardiac events: the VELETI II randomized clinical trial. Presenter: J. Rodes Cabal.   Non-obstructive SVG lesions affect mid-term prognosis negatively. There is little evidence on the safety and efficacy of non-obstructive intermediate SVG lesions<a href="https://solaci.org/en/2016/05/20/veleti-ii-pci-to-intermediate-coronary-svg-lesions-with-des/" title="Read more" >...</a>

LEADERS FREE ACS: Biolimus coated stent vs. bare metal stent in ACS with high bleeding risk

Original Title: Biolimus A9 drug-coated stent vs. bare metal stent in patients presenting with ACS. A pre-specified LEADERS FREE ACS sub-study. Presenter: C.K. Naber.   In ACS patients with high bleeding risk, guidelines recommend 3 to 6 months of dual ATP treatment for DES implantation or one month in case of conventional stenting.   The<a href="https://solaci.org/en/2016/05/19/leaders-free-acs-biolimus-coated-stent-vs-bare-metal-stent-in-acs-with-high-bleeding-risk/" title="Read more" >...</a>

Good outcomes of bioresorbable scaffolds in off-label cases

Original Title: Clinical outcomes following “off-label” versus “established” indication of bioresorbable scaffolds for treatment of coronary artery disease in a real-world population. Reference: Tadashi Miyazaki, et al EuroIntervention 2016;11:475-478.   Courtesy of Dr. Carlos Fava.   Bioresorbable scaffolds (BSB) have shown their benefit in different studies, but there is little information available on “off label”<a href="https://solaci.org/en/2016/05/10/good-outcomes-of-bioresorbable-scaffolds-in-off-label-cases/" title="Read more" >...</a>

Safety of High Pressure Post-dilation in Bioresorbable Scaffolds

Original Title: Is High Pressure Postdilation Safe in Bioresorbable Vascular Scaffolds? Optical Coherence Tomography Observations After Noncompliant Balloons Inflated at More than 24 Atmospheres. Reference: Enrico Fabris et al. Catheter Cardiovasc Interv. 2016 Apr;87(5):839-46. Courtesy of Dr. José Amadeo Guillermo Álvarez. The mechanical properties of bioresorbable vascular scaffolds (BVS) are different from those of bare<a href="https://solaci.org/en/2016/05/02/safety-of-high-pressure-post-dilation-in-bioresorbable-scaffolds/" title="Read more" >...</a>

Mortality Reduction with Vena Cava Filters

Original Title: Outcomes after Vena Cava Filter Use in Non-Cancer Patients with Acute Venous Thromboembolism: A Population-Based Study. Reference: Richard H. White et al. Circulation. 2016 Apr 5. Epub ahead of print. The evidence on the benefits of vena cava filters is limited. This retrospective study analyzed all patients with baseline oncological processes admitted to<a href="https://solaci.org/en/2016/04/13/mortality-reduction-with-vena-cava-filters/" title="Read more" >...</a>

New Meta-Analysis Shows Similar Mortality between Bivalirudin and Heparin

This meta-analyzis of contemporary studies comparing the safety and efficacy of bivalirudin vs. heparin showed no differences in mortality between the two drugs and, consistently with other studies, bivalirudin was associated with an increased risk of acute stent thrombosis. During ACC 2015, the MATRIX study did succeed in showing global differences between the two drugs<a href="https://solaci.org/en/2016/04/08/new-meta-analysis-shows-similar-mortality-between-bivalirudin-and-heparin/" title="Read more" >...</a>

¿Desescalar la doble antiagregación es el nuevo paradigma?

Optimal Duration of Dual Antiplatelet Therapy: New ACC-AHA Guidelines

Original Title: 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients with Coronary Artery Disease. Reference: Levine GN et al. Circulation. 2016 Mar 29. [Epub ahead of print]. Courtesy of Dr. Alejandro Lakowsky. The new ACC-AHAGuidelines on the optimal duration of dual antiplatelet therapy(DAPT) in patients with coronary artery disease have just been<a href="https://solaci.org/en/2016/04/01/optimal-duration-of-dual-antiplatelet-therapy-new-acc-aha-guidelines/" title="Read more" >...</a>

Which intraprocedural thrombotic events impact PCI outcomes

Original Title: Which Intraprocedural Thrombotic Events Impact Clinical Outcomes After Percutaneous Coronary Intervention in Acute Coronary Syndromes? A Pooled Analysis of the HORIZONS-AMI and ACUITY Trials. Reference: Jeffrey D. Wessler et al. JACC Cardiovasc Interv. 2016 Feb 22;9(4):331-7. Courtesy of Dr. Agustín Vecchia. Intraprocedural thrombotic events (IPTEs) indicate short and term prognosis in PCI patients. This<a href="https://solaci.org/en/2016/03/23/which-intraprocedural-thrombotic-events-impact-pci-outcomes/" title="Read more" >...</a>

High bleeding risk: is BMS still justifiable?

Original Title: Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention? A Pre-Specified Analysis From the ZEUS Trial. Reference: Sara Ariotti et al. J Am Coll Cardiol Intv. 2016;9(5):426-436.   This work studied ischemic and bleeding events in high bleeding risk patients randomized to the zotarolimus eluting stent (ZEZ) Endeavor<a href="https://solaci.org/en/2016/03/15/high-bleeding-risk-is-bms-still-justifiable/" title="Read more" >...</a>